Orthocell has today announced global distribution partner BioHorizons has recorded a fast transition to first sales of Striate+\u2122 in the key market of Canada, following regulatory approval in early July. Striate+ can now be used in Canada in dental guided bone and tissue regeneration procedures.<\/p>\n
The Canadian market alone is estimated to be worth AU$60 million, with the global market opportunity for Striate estimated to be in excess of AU$1 billion.<\/p>\n
Orthocell Managing Director, Paul Anderson, said:<\/p>\n
\u201cCommencement of sales in Canada is further validation of Orthocell\u2019s expanding global footprint. Our valued partner BioHorizons has executed a rapid transition from approval to first sales. This reaffirms the high-quality nature of our product and partnership. Once Singapore and Brazil applications are approved, Striate+ will be available for use in guided bone and tissue repair in seven large and attractive markets. And we will continue to accelerate approvals in what is a significant AU$1 billion annual global market.\u201d<\/p>\n